Literature DB >> 26615334

Construction of Nef-positive doxycycline-dependent HIV-1 variants using bicistronic expression elements.

Yme U van der Velden1, Wendy Kleibeuker1, Alex Harwig1, Bep Klaver1, Esther Siteur-van Rijnstra1, Esmay Frankin1, Ben Berkhout1, Atze T Das2.   

Abstract

Conditionally replicating HIV-1 variants that can be switched on and off at will are attractive tools for HIV research. We previously developed a genetically modified HIV-1 variant that replicates exclusively when doxycycline (dox) is administered. The nef gene in this HIV-rtTA variant was replaced with the gene encoding the dox-dependent rtTA transcriptional activator. Because loss of Nef expression compromises virus replication in primary cells and precludes studies on Nef function, we tested different approaches to restore Nef production in HIV-rtTA. Strategies that involved translation via an EMCV or synthetic internal ribosome entry site (IRES) failed because these elements were incompatible with efficient virus replication. Fusion protein approaches with the FMDV 2A peptide and human ubiquitin were successful and resulted in genetically-stable Nef-expressing HIV-rtTA strains that replicate more efficiently in primary T-cells and human immune system (HIS) mice than Nef-deficient variants, thus confirming the positive effect of Nef on in vivo virus replication.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2A peptide; HIS mouse; HIV; IRES; Nef; Protein production; Tet-On system; Ubiquitin

Mesh:

Substances:

Year:  2015        PMID: 26615334     DOI: 10.1016/j.virol.2015.11.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

Review 1.  Tet-On Systems For Doxycycline-inducible Gene Expression.

Authors:  Atze T Das; Liliane Tenenbaum; Ben Berkhout
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391

Review 2.  Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises.

Authors:  Aoife K O'Connell; Florian Douam
Journal:  Vaccines (Basel)       Date:  2020-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.